Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TK-8001 |
Synonyms | |
Therapy Description |
TK-8001 is a T-cell receptor-based therapy that targets melanoma-associated antigen 1 (MAGE-A1) expressed on tumor cells, potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TK-8001 | TK 8001|TK8001 | TK-8001 is a T-cell receptor-based therapy that targets melanoma-associated antigen 1 (MAGE-A1) expressed on tumor cells, potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05430555 | Phase Ib/II | TK-8001 | A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic MAGE-A1+ Solid Tumors (IMAG1NE) | Terminated | NLD | GBR | ESP | DEU | BEL | 0 |